Singapore Institute of Advanced Medicine Holdings Ltd: Material Variances Identified Between FY2025 Audited and Unaudited Financial Statements
Link: https://links.sgx.com/1.0.0/corporate-announcements/F1HDSZK4739D6224/85ac33198e29902bb2480bce01fff88786d7e74d384fe24243085d72ff7edb9a
Summary:
-
Board announces significant differences between unaudited and audited figures for FY2025 following final audit completion, with details shared per SGX Catalist Rule 704(5).
-
Biggest variance: Other gains/(losses) reduced by S$893,631 after reclassification of fair value gains and modification gains on loans from profit/loss to equity (no impact to total equity).
-
Loss before tax increased to S$27.05 million in audited accounts, up S$893,631 from unaudited results; loss per share slightly higher at 2.57 Singapore cents.
-
Other reserves and accumulated losses adjusted to reflect reclassification; total equity remains unchanged.
-
Net cash generated from financing activities reclassified to exclude restricted cash, now reported under financing activities instead of cash equivalents (no effect on overall cash/bank balances).
-
Board also clarifies financial effects of proposed transactions (Caterine debt conversion, placement of new shares): projected loss per share reduced after equity infusions from these transactions.
-
Shareholders are advised to read full audited results for FY2025 and exercise caution before making investment decisions; listed on SGX Catalist, IPO sponsored by PrimePartners Corporate Finance.
-
Announcement issued by CEO Dr Djeng Shih Kien, dated 9 October 2025, includes standard SGX disclaimer and sponsor contact.